The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

During the session, Ray told the story of why this patient initially refused treatment and how he convinced her that she was worthy of survival. “When we think about ASCO, we think about science, ...

Data from the long-running HOME study links higher exposure to certain polyfluoroalkyl substances ‘forever chemicals’ with ...

A higher intake of several food colouring additives is associated with an increased risk of developing type 2 diabetes, an ...

Endovascular thrombectomy with medical management improves functional independence vs medical management alone in stroke due ...

From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart ...

The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...

She’d diagnosed rheumatoid arthritis dozens of times but dismissed her own symptoms and fought her eventual diagnosis. Today ...

Backed by 26 ministries and GRADE evidence, PAHO's new clinical pathway could accelerate access to SGLT2 inhibitors and ...

Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis ...

A French study shows that kidney biopsy during early pregnancy appears safe — with only one patient with serious bleeding ...